RayBiotech, Inc. Announces New Diagnostic Core Facility Partnering Program
NORCROSS, Ga., April 19, 2012 /PRNewswire/ — RayBiotech, Inc. today announced that it has formally launched a partnering program for select diagnostic core facilities at academic and government research institutes in the United States and Canada. Under the terms of the partnership program, core diagnostics facilities will be able to provide proprietary RayBiotech proteomic analysis services as a component of their current services offerings at no cost to the core facilities. These services will be provided to select cores which emphasize biomarker and proteomic analysis to their affiliated researchers. Services such as RayBiotech’s Quantibody® characterization of biomarker expression will be emphasized, but all of RayBiotech’s services portfolio will be available for pass-through to core clients, including ELISA and phosphorylation array testing. The ultimate goal of this program will be to aid researchers in accelerating drug discovery, drug target validation and disease-related efforts with an emphasis on impacting cancer and other disease-specific research initiatives. The program will be offered exclusively to cores in North America.
Commenting on the new program, RayBiotech’s President, COO and Co-founder, Rani Huang, said, “Since the founding of RayBiotech over ten years ago we have had numerous longstanding and productive relationships with academic and governmental research institutes. This is our effort to give back to these partners and to establish new relationships with cutting-edge cores willing to adapt our platforms into their diagnostic services programs.”
About RayBiotech, Inc.
RayBiotech (www.raybiotech.com) pioneered the development of antibody and protein array technologies and provides reliable high-throughput platforms for identifying disease mechanisms, screening and validation of novel biomarkers and identification of new drug targets. In 2001 RayBiotech introduced the first commercially available cytokine antibody array. Since then, RayBiotech array products have been featured in hundreds of publications, including some in top-tier journals: Nature, Nature Medicine, Cell, Lancet, PNAS (USA), and many others. Offering more antibody array choices than any of its competitors, RayBiotech has established a leading reputation for the high quality and innovative developments provided to the research community. RayBiotech continues to lead in the development of protein array technologies and is focused on further meeting the needs of clients in translating new knowledge of human biology to improved health. A spin-off from Emory University’s School of Medicine, RayBiotech is privately owned, with headquarters in metropolitan Atlanta (Norcross, GA).
For More Information:
Rob Burgess, PhD
Director, Business Development
SOURCE RayBiotech, Inc.